Skeletal muscle reprogramming in peripheral nerve injury: mechanisms, therapeutic roles, and complication management
Experimental Biology and Medicine · 02.03.2026 · 251
DOI: 10.3389/ebm.2026.10835 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Experimental Biology and Medicine, online erschienen am 02.03.2026. Verfasst von Fuqiang Long und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Burns and Plastic Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, China. Hauptthemen laut MEDLINE: Peripheral Nerve Injuries, Muscle, Skeletal, Cellular Reprogramming. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 175 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Peripheral nerve injury (PNI) presents a significant clinical challenge, frequently leading to long-term neuromuscular dysfunction, muscle atrophy, fibrosis, and chronic pain. Traditional repair strategies, including microsurgical reconnection and neurotrophic support, often yield limited functional recovery, especially in cases of delayed or incomplete reinnervation. In this context, skeletal muscle reprogramming—defined as the intentional modulation of cellular fate, function, or metabolic state in muscle-resident cells—has emerged as a promising strategy to enhance regenerative outcomes. This process involves transcriptional, epigenetic, and metabolic interventions targeting myogenic progenitors, fibro-adipogenic progenitors (FAPs), satellite cells (MuSCs), and the broader muscle microenvironment. Recent studies demonstrate that reprogramming strategies can mitigate denervation-induced muscle atrophy, delay fibrotic remodeling, promote neuromuscular junction (NMJ) reconstruction, and even stimulate endogenous nerve regrowth via retrograde signaling. Mechanistic insights have uncovered pivotal roles for signaling pathways such as Wnt/β-catenin, TGF-β, Notch, and HDAC-regulated chromatin dynamics. Furthermore, innovations in small molecule cocktails, CRISPR-based transcriptional reactivation, and metabolic rewiring have expanded the therapeutic toolkit for muscle preservation and regeneration. This review comprehensively examines the molecular mechanisms, therapeutic roles, and translational challenges of skeletal muscle reprogramming in the context of PNI. We explore how muscle-targeted interventions can address complications of denervation, improve the efficacy of nerve repair, and offer a synergistic axis of regeneration when integrated with nerve-centric strategies. Finally, we identify key knowledge gaps and outline future research directions required to translate reprogramming-based therapies into clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Burns and Plastic Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
- The 2011 Collaborative Innovation Center of Tissue Damage Repair and Regeneration Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
- The Collaborative Innovation Center of Tissue Damage Repair and Regeneration Medicine, Zunyi Medical University, Zunyi, China.
Zitieren
APA
Long, F., Pan, X., He, A., Wang, X., Wei, Z., & Gao, S. (2026). Skeletal muscle reprogramming in peripheral nerve injury: mechanisms, therapeutic roles, and complication management. Experimental Biology and Medicine, 251. https://doi.org/10.3389/ebm.2026.10835
Vancouver
Long F, Pan X, He A, Wang X, Wei Z, Gao S. Skeletal muscle reprogramming in peripheral nerve injury: mechanisms, therapeutic roles, and complication management. Experimental Biology and Medicine. 2026;251. doi:10.3389/ebm.2026.10835
BibTeX
@article{Long2026,
author = {Long, Fuqiang and Pan, Xiaoru and He, Anxin and Wang, Xinlu and Wei, Zairong and Gao, Shaoying},
title = {Skeletal muscle reprogramming in peripheral nerve injury: mechanisms, therapeutic roles, and complication management},
journal = {Experimental Biology and Medicine},
year = {2026},
volume = {251},
doi = {10.3389/ebm.2026.10835}
}
EUVIMED